HTA and market access

Showing 9 of 0 results

• Characterisation of oncology EHR-derived real-world data in the UK, Germany, and Japan

  ESMO Real-World Data and Digital Oncology

  • Real-world evidence
  • Publication summary
  • Publications
  • Data science
  • Methodology
  • HTA and market access
• Unicancer and Flatiron Health partner to accelerate regulatory-grade evidence generation from international Real-World Data
  • Press releases
  • HTA and market access
• Evaluating transportability of overall survival estimates from US to UK populations receiving first-line treatment for advanced non-small cell lung cancer: a retrospective cohort study

  BMJ Open

  • Publication summary
  • Publications
  • Non-small cell lung cancer
  • HTA and market access
• Unlocking the power of real-world data across the globe: Recent research accomplishments from Flatiron FORUM and multinational data
  • Real-world evidence
  • HTA and market access
• Filling critical evidence generation gaps with global oncology real-world data
  • Real-world evidence
  • Video
  • HTA and market access
• Assessing real-world data from electronic health records for health technology assessment: The SUITABILITY checklist: a good practices report of an ISPOR task force

  Value in Health

  • Publication summary
  • Publications
  • Data science
  • Methodology
  • Regulatory
  • HTA and market access
  • AP - Blythe Adamson, MPH, PhD
• Transporting comparative effectiveness evidence between countries: considerations for health technology assessment

  Pharmacoeconomics

  • Real-world evidence
  • Video
  • Publication summary
  • Publications
  • HTA and market access
• Evaluation of US oncology electronic health record real-world data to reduce uncertainty in health technology appraisals: a retrospective cohort study

  BMJ Open

  • Real-world evidence
  • Publication summary
  • Publications
  • Methodology
  • HTA and market access
• Transportability of overall survival estimates from US to UK populations receiving first-line treatment for advanced non-small-cell lung cancer

  ISPOR EU

  • Real-world evidence
  • Publication summary
  • Publications
  • Methodology
  • HTA and market access